We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-6.36%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.32B
AUM Growth
-$289M
Cap. Flow
-$25.4M
Cap. Flow %
-1.92%
Top 10 Hldgs %
77.26%
Holding
47
New
9
Increased
7
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
AGMB
AgomAb Therapeutics NV
AGMB
+$22M
2
GRAL
GRAIL Inc
GRAL
+$17.8M
3
TXG icon
10x Genomics
TXG
+$17.5M
4
QGEN icon
Qiagen
QGEN
+$17M
5
PSNL icon
Personalis
PSNL
+$13.5M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$72.1M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$18.6M
3
UNH icon
UnitedHealth
UNH
+$16.5M
4
DXCM icon
DexCom
DXCM
+$11.6M
5
CI icon
Cigna
CI
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

1 2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Casdin Capital held 47 positions worth $1.32B, down 18% from $1.61B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Casdin Capital's Q1 2026 filing shows 9 new, 7 increased, 4 reduced and 7 closed positions. Its largest new stake was AgomAb Therapeutics NV: 1,550,000 shares worth $16.3M. The largest sale was Avidity Biosciences, an estimated $72.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Casdin Capital's largest Q1 2026 buy was AgomAb Therapeutics NV: 1,550,000 shares worth $16.3M.
  • Casdin Capital added most to 10x Genomics in Q1 2026, an estimated $17.5M increase.
  • Casdin Capital's biggest Q1 2026 reduction was Illumina, cutting an estimated $9.19M.
  • Casdin Capital fully exited Avidity Biosciences in Q1 2026, selling an estimated $72.1M.
  • Casdin Capital's ten largest holdings make up 77% of its $1.32B portfolio in Q1 2026.
  • Casdin Capital opened 9 new positions and closed 7 in Q1 2026.
  • Casdin Capital's portfolio value fell 18% quarter-over-quarter to $1.32B.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.